The IPS, the IPS-CTLA4 score, the IPS-PD1 blocker score, and the IPS-CTLA4+PD1 blocker score were significantly higher in cluster 2 than in cluster 1 (Figure 5G–5J, p<0.01), which demonstrated a more immunogenic phenotype in cluster 2, suggesting that immunotherapy might be more beneficial to PCa patients in cluster 2. Here, CTLA4 is linked to posterior cortical atrophy.